Tempus AI, Inc. reported significant financial growth in its latest quarterly results, with total net revenue reaching $334.2 million for the three months ended September 30, 2025, compared to $180.9 million for the same period in 2024, marking an increase of 85%. The company's revenue for the nine months ended September 30, 2025, also saw substantial growth, totaling $904.6 million, up from $492.7 million in the prior year. The increase in revenue was primarily driven by a surge in genomic testing volumes, particularly due to the acquisition of Ambry Genetics, which contributed to a rise in both the number of tests performed and average revenue per test.
Despite the revenue growth, Tempus reported a net loss of $80.0 million for the third quarter of 2025, slightly higher than the $75.8 million loss recorded in the same quarter of the previous year. For the nine-month period, the net loss was $190.9 million, a significant reduction from the $692.8 million loss reported in the prior year. The company attributed the ongoing losses to high operational costs, including increased personnel expenses and costs associated with recent acquisitions, which included Ambry Genetics and Paige.AI.
In terms of strategic developments, Tempus completed several acquisitions in 2025, including Ambry Genetics and Paige.AI, which are expected to enhance its capabilities in genomic testing and digital pathology. The company also entered into a Controlled Equity Offering Sales Agreement, allowing it to sell up to $500 million in Class A common stock, and raised $726.5 million through a private offering of convertible senior notes. These strategic moves are aimed at bolstering its financial position and expanding its market presence.
Operationally, Tempus reported a significant increase in the volume of genomic tests, with approximately 217,000 tests performed in the third quarter of 2025, compared to about 69,000 in the same quarter of 2024. The company also noted that it has worked with over 200 biotech companies and 19 of the 20 largest public pharmaceutical companies, indicating a strong market presence. The total employee headcount has also increased, reflecting the company's growth and expansion efforts.
Looking ahead, Tempus remains focused on leveraging its acquisitions to enhance its product offerings and expand its market share. The company anticipates continued investment in research and development to drive innovation and improve operational efficiencies. Management believes that the existing cash reserves, along with anticipated cash flows from operations, will be sufficient to support its operational plans for at least the next year, although the company acknowledges the need for ongoing capital to fund its growth initiatives.
About Tempus AI, Inc.
Tempus AI is a healthcare technology company specializing in precision medicine through Intelligent Diagnostics. It combines AI, genomic, clinical, and imaging data to develop personalized, accurate laboratory tests across oncology, neuropsychiatry, cardiology, and infectious diseases. Its platform integrates vast multimodal datasets, enabling data-driven therapy decisions, clinical trial matching, and drug discovery, serving healthcare providers, researchers, and life sciences companies worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.